These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27000270)

  • 21. [French Health Authority guide].
    Bouvenot G; Dubernard JM; Rochaix L
    Therapie; 2012; 67(5):407. PubMed ID: 23241249
    [No Abstract]   [Full Text] [Related]  

  • 22. Industry must communicate value and contribution of drugs to Congress and public.
    Gatty B
    Hosp Formul; 1994 May; 29(5):406, 405. PubMed ID: 10133903
    [No Abstract]   [Full Text] [Related]  

  • 23. [Medications: dear and expensive?].
    Rojahn J
    Klin Monbl Augenheilkd; 2014 Feb; 231(2):108-13. PubMed ID: 25298981
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 25. US health reform and value: hit or miss?
    Braithwaite RS
    Expert Rev Pharmacoecon Outcomes Res; 2010 Oct; 10(5):477-80. PubMed ID: 20950060
    [No Abstract]   [Full Text] [Related]  

  • 26. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
    Beatty PA; Laking GR
    J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
    [No Abstract]   [Full Text] [Related]  

  • 27. Patent protection for medical technologies: why some and not others?
    Melzer D
    Lancet; 1998 Feb; 351(9101):518-9. PubMed ID: 9482467
    [No Abstract]   [Full Text] [Related]  

  • 28. [Drug safety and post-marketing control. Developments since the reform of the 1978 drug regulation].
    Wille H; Schönhöfer PS
    Internist (Berl); 2002 Apr; 43(4):469-70, 473-81. PubMed ID: 12053403
    [No Abstract]   [Full Text] [Related]  

  • 29. Safe drugs and the cost of good intentions.
    Eichler HG; Abadie E; Raine JM; Salmonson T
    N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718
    [No Abstract]   [Full Text] [Related]  

  • 30. Payers begin to make plans for coming wave of biosimilars.
    Carroll J
    Manag Care; 2010 Jun; 19(6):7-8, 10. PubMed ID: 20608402
    [No Abstract]   [Full Text] [Related]  

  • 31. Regulatory assessment of new drugs in developing countries.
    Pandolfini C; Bonati M; Reggi V; Figueras A
    Lancet; 2003 Jul; 362(9379):249-50. PubMed ID: 12885499
    [No Abstract]   [Full Text] [Related]  

  • 32. [Official experimental testing of biomedical products. Regulatory frame and importance of for quality, safety and efficacy].
    Vieths S; Seitz R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1133-8. PubMed ID: 25123139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Niche markets and evidence assessment in transition: a critical review of proposed drug reforms.
    Gibson SG; Lemmens T
    Med Law Rev; 2014; 22(2):200-20. PubMed ID: 24841527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

  • 35. [Approval of drugs by national and European agencies--sequelae for the pharmaceutical industry].
    Zierenberg O
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):596-600. PubMed ID: 9527448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent reforms of the German health care system.
    Schölkopf M
    World Hosp Health Serv; 2004; 40(2):12-3. PubMed ID: 15338991
    [No Abstract]   [Full Text] [Related]  

  • 37. Regulatory watch: Where do new medicines originate from in the EU?
    Lincker H; Ziogas C; Carr M; Porta N; Eichler HG
    Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298
    [No Abstract]   [Full Text] [Related]  

  • 38. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 40. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.